Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dominika Nádaská has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Integrated Structural, Physicochemical, Pharmacokinetic and Pharmacodynamic Evaluation of Substituted Phenylcarbonyloxypiperazinopropanols as Antimycobacterial Agents

    by Dominika Nádaská, Tomáš Sádecký, Lucia Račková, Martina Hrčka Dubničková, Fils Andriamainty, Petr Mokrý, Simona Gover, Vladimír Garaj, Jozef Csöllei, Ivan Malík

    This research aimed to evaluate structural, physicochemical and pharmacokinetic characteristics of racemic 2-hydroxy-3-(4-phenylpiperazin-1-yl)propyl 4-[(alkoxycarbonyl)amino]benzoates (Ib)–(IVb) and 2-hydroxy-3-[4-(R-substituted phenyl)piperazin-1-yl]propyl 4-[(alkoxycarbonyl)amino]benzoates (1b)–(12b), while further extending the in vitro screening of their racemic salts, 1-(3-{4-[(alkoxycarbonyl)amino]benzoyloxy}-2-hydroxypropyl)-4-(R-substituted phenyl)piperazin-1-ium chlorides (I)–(IV) and (1)–(12) (alkoxy = methoxy to butoxy in all of these series, and R = H, 4′-F, 2′-F or 2′-OCH3), against several mycobacterial species, including a slow-growing virulent Mycobacterium tuberculosis (Mtb) H37Rv strain. The values of structural, physicochemical and several pharmacokinetic descriptors of the compounds (Ib)–(IVb) and (1b)–(12b) were generated in silico, employing a palette of interactive web-based engines and standalone software packages. The obtained data allowed for exploration of their mutual relationships through a chemometric principal component analysis method. The predicted outputs were compared to the values of respective descriptors defining antimycobacterial drugs approved worldwide for therapeutic use in human medicine. Molecular docking (MD) analyses were carried out to explore the possibilities of whether particular (R)- and (S)-stereoisomers of non-protonated derivatives, as well as (R)- and (S)-stereoisomeric forms of their salts (I)–(IV) and (1)–(12) would effectively interact with a proposed pharmacological target, adenosine 5′-triphosphate (ATP) synthase. This membrane–protein complex was considered essential for energy metabolism and survival of various mycobacterial species. Respecting the fundamental structural arrangement of more efficient salts, the importance of their structural and spatial features was highlighted to achieve relative effective interactions with particular subunits of ATP synthase present in Mtb H37Rv. The results of the MD evaluations could contribute to the understanding of how these compounds inhibited growth of Mtb H37Rv. 1-(3-{4-[(Butoxycarbonyl)amino]benzoyloxy}-2-hydroxypropyl)-4-phenylpiperazin-1-ium chloride (IV) with a minimum inhibitory concentration (MIC) value of 62.5 μM estimated in vitro and 1-(3-{4-[(butoxycarbonyl)amino]benzoyloxy}-2-hydroxypropyl)-4-(2-methoxyphenyl)piperazin-1-ium chloride (12) with MIC = 16 μM, as the most effective anti-Mtb H37Rv agents of each series of the salts, were screened in vitro to investigate their antiproliferative or (eventual) cytotoxic properties using a normal human dermal fibroblast cell line. The derivative (IV) decreased cell viability slightly more compared to the molecule (12).

  • Open Access

    New N-Arylpiperazine-Based Compounds as Potential Inhibitors of Purinergic P2X7-Associated Signaling

    by Gabriela Greifová, Martina Hrčka Dubničková, Dominika Nádaská, Róbert Šandrik, Iva Kapustíková, Emil Švajdlenka, Martin Pisárčik, Jozef Csöllei, Ivan Malík

    This research paper focused on the synthesis of 1-[2-hydroxy-3-(phenylcarbamoyloxy)propyl]-4-(R1, R2-substituted phenyl)piperazin-1-ium chlorides (I)–(III), containing R1, R2 = H, Cl and/or OCH3, and the evaluation of some of their physicochemical parameters. The in vitro biological investigation of these N-arylpiperazine (NAP) derivatives consisted in assessing their impact on purinergic P2X7-associated signaling, that is, the evaluation of antioxidant, anti-inflammatory and immunomodulatory characteristics. The ultraviolet type C (UVC) irradiation (λ = 254 nm, 0.954 kJ/m2) induced a pronounced stress response in human leukocytes without marked cytotoxicity while maintaining high cell viability (≥90%), as evidenced by increased interleukin (IL)-1β production (94%), elevated IL-1β mRNA expression, enhanced lipid peroxidation (66%), and increased intracellular adenosine 5′-triphosphate (ATP; 97%), respectively. Under basal conditions, these lipophilic NAPs, defined with logarithmic values of retention (capacity) factors corresponding to 100% water in isocratic elution RP-HPLC, i.e., kw descriptors (varying from 2.3829 to 4.3689), and isocratic chromatographic hydrophobicity index (φ0) parameters (ranging from 0.7578 to 0.8842), reduced IL-1β production (by 26–63%) and enhanced superoxide dismutase (SOD) activity (up to 64%) without inducing oxidative damage. Under UVC-induced stress, all evaluated compounds decreased lipid peroxidation (up to 45%) and significantly increased antioxidant enzyme activities, including SOD (up to 223%) as well as catalase (up to 145%). The observed effects were associated with changes in intracellular ATP levels and redox-related parameters. In the experiments described in this paper, intracellular ATP was measured so that no direct conclusions could be drawn regarding the extracellular ATP-dependent activation of purinergic receptors, including P2X7. Overall, the results demonstrated that variations within the structure of these NAPs significantly affected compounds’ biological activity, highlighting their potential for further optimization as cytoprotective and anti-inflammatory agents.

  • Open Access

    Insight into the in Silico Structural, Physicochemical, Pharmacokinetic and Toxicological Properties of Antibacterially Active Viniferins and Viniferin-Based Compounds as Derivatives of Resveratrol Containing a (2,3-Dihydro)benzo[b]furan Privileged Scaffold

    by Dominika Nádaská, Ivan Malík

    Resistance of various bacterial pathogens to the activity of clinically approved drugs currently leads to serious infections, rapid spread of difficult-to-treat diseases, and even death. Taking the threats for human health in mind, researchers are focused on the isolation and characterization of novel natural products, including plant secondary metabolites. These molecules serve as inspiration and a suitable structural platform in the design and development of novel semi-synthetic and synthetic derivatives. All considered compounds have to be adequately evaluated in silico, in vitro, and in vivo using relevant approaches. The current review paper briefly focuses on the chemical and metabolic properties of resveratrol (1), as well as its oligomeric structures, viniferins, and viniferin-based molecules. The core scaffolds of these compounds contain so-called privileged structures, which are also present in many clinically approved drugs, indicating that those natural, properly substituted semi-synthetic, and synthetic molecules can provide a notably broad spectrum of beneficial pharmacological activities, including very impressive antimicrobial efficiency. Except for spectral verification of their structures, these compounds suffer from the determination or prediction of other structural and physicochemical characteristics. Therefore, the structure–activity relationships for specific dihydrodimeric and dimeric viniferins, their bioisosteres, and derivatives with notable efficacy in vitro, especially against chosen Gram-positive bacterial strains, are summarized. In addition, a set of descriptors related to their structural, physicochemical, pharmacokinetic, and toxicological properties is generated using various computational tools. The obtained values are compared to those of clinically approved drugs. The particular relationships between these in silico parameters are also explored.


  • Open Access

    Research in the Field of Drug Design and Development

    by Grazyna Biala, Ewa Kedzierska, Marta Kruk-Slomka, Jolanta Orzelska-Gorka, Sara Hmaidan, Aleksandra Skrok, Jakub Kaminski, Eva Havrankova, Dominika Nadaska, Ivan Malik

    The processes used by academic and industrial scientists to discover new drugs have recently experienced a true renaissance, with many new and exciting techniques being developed over the past 5–10 years alone. Drug design and discovery, and the search for new safe and well-tolerated compounds, as well as the ineffectiveness of existing therapies, and society’s insufficient knowledge concerning the prophylactics and pharmacotherapy of the most common diseases today, comprise a serious challenge. This can influence not only the quality of human life, but also the health of whole societies, which became evident during the COVID-19 pandemic. In general, the process of drug development consists of three main stages: drug discovery, preclinical development using cell-based and animal models/tests, clinical trials on humans and, finally, forward moving toward the step of obtaining regulatory approval, in order to market the potential drug. In this review, we will attempt to outline the first three most important consecutive phases in drug design and development, based on the experience of three cooperating and complementary academic centers of the Visegrád group; i.e., Medical University of Lublin, Poland, Masaryk University of Brno, Czech Republic, and Comenius University Bratislava, Slovak Republic.